Radiopharmaceutical
News/ News/ News/ Oncology/ Sales and Marketing
Manufacturing foul-up hits Novartis’ radioligand business
Phil Taylor
Lutathera, manufacturing, Novartis, Oncology, Pluvicto, Radiopharmaceutical
0 Comment
UK grants early access to Novartis’ prostate cancer radioligand
Phil Taylor
Advanced Accelerator Applications, Early Access to Medicines Scheme, MHRA, Novartis, Pluvicto, Prostate cancer, Radiopharmaceutical, UK
0 Comment
Novartis gets first OK for radioligand Pluvicto in prostate cancer
Phil Taylor
Novartis, Oncology, Pluvicto, Prostate cancer, Radiopharmaceutical, regulatory approval
0 Comment
Belgium’s Precirix raises €80m to fund radiopharma aspirations
Phil Taylor
Belgium, Biotech, financing, Oncology, Precirix, Radiopharmaceutical
0 Comment
Bayer props up sagging radionuclide business with Noria acquisition
Phil Taylor
Bayer, M&A, Oncology, Prostate cancer, radionuclide, Radiopharmaceutical
0 Comment
ASCO21: Novartis’ prostate cancer radiotherapy extends survival
Phil Taylor
177Lu-PSMA-617, ASCO 2021, Novartis, Oncology, Prostate cancer, Radiopharmaceutical
0 Comment
Novartis expands in radio-oncology again with $1.3bn Artios alliance
Phil Taylor
Artios, Novartis, Oncology, partnering, precision medicine, radiology, Radiopharmaceutical
0 Comment
Novartis builds radio-oncology pipeline with iTheranostics deal
Phil Taylor
iTheranostics, Novartis, Oncology, radiology, Radiopharmaceutical
0 Comment